103 related articles for article (PubMed ID: 6595924)
1. Prediction of survival in breast cancer. Principles and current status of hormone receptors and DNA content as prognostic factors.
Adami HO; Killander D
Acta Chir Scand Suppl; 1984; 519():25-34. PubMed ID: 6595924
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.
Thorpe SM; Rose C
Cancer Surv; 1986; 5(3):505-25. PubMed ID: 3555780
[TBL] [Abstract][Full Text] [Related]
3. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
4. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
Masood S
Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
[TBL] [Abstract][Full Text] [Related]
5. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cathepsin-D expression in female breast cancer.
Aaltonen M; Lipponen P; Kosma VM; Aaltomaa S; Syrjänen K
Anticancer Res; 1995; 15(3):1033-7. PubMed ID: 7645922
[TBL] [Abstract][Full Text] [Related]
7. Progesterone and estrogen receptors as prognostic variables in breast cancer.
Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG
Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609
[TBL] [Abstract][Full Text] [Related]
8. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour.
Colpaert C; Vermeulen P; Jeuris W; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E
J Pathol; 2001 Apr; 193(4):442-9. PubMed ID: 11276002
[TBL] [Abstract][Full Text] [Related]
9. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
Cherubini M; Baxa P; Guarino G
Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive factors in breast cancer.
Bundred NJ
Cancer Treat Rev; 2001 Jun; 27(3):137-42. PubMed ID: 11417963
[TBL] [Abstract][Full Text] [Related]
11. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in primary breast cancer.
McGuire WL
Cancer Surv; 1986; 5(3):527-36. PubMed ID: 3555781
[TBL] [Abstract][Full Text] [Related]
13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
14. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
15. Survival of women with node negative breast cancer in the Auckland region.
Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ
Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458
[TBL] [Abstract][Full Text] [Related]
19. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
[TBL] [Abstract][Full Text] [Related]
20. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]